Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib and radiotherapy in newly diagnosed glioblastoma
ISRCTN52658296Phase 2Completed
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Mar 2015
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of olaparib in glioblastoma (GBM) and glioma (3 arms), sponsored by NHS Greater Glasgow and Clyde. Primary endpoints: Recommended dose of olaparib with radiotherapy and Overall survival. Started Mar 2015; status: completed.
02
Drugs
olaparib
03
Conditions
glioblastoma (GBM)glioma
Beyond the preview
Go deeper on ISRCTN52658296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN52658296.